P42 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, FROM MONUMENTAL-1

P42 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, FROM MONUMENTAL-1

Bibliographic Details
Main Authors:	N. van de Donk, L. Rasche, C. Touzeau, A. Chari, C. Schinke, M. Minnema, J. Berdeja, A. Oriol, P. Rodriguez-Otero, E. Askari, M. Mateos, L. Costa, J. Caers, A. Krishnan, D. Vishwamitra, J. Ma, X. Qin, K.S. Gries, K. Kato, M. Campagna, T. Masterson, B. Hilder, J. Tolbert, T. Renaud, J. Goldberg, C. Heuck, P. Moreau, J. San-Miguel
Format:	Article
Language:	English
Published:	Wiley 2023-05-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000936296.64225.1c

Similar Items

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (MONUMENTAL-1)
by: M.C. Minnema, et al.
Published: (2023-05-01)

S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
by: Cyrille Touzeau, et al.
Published: (2023-08-01)

S182: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED EFFICACY AND SAFETY RESULTS FROM MONUMENTAL-1
by: M. C. Minnema, et al.
Published: (2022-06-01)

P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL-1
by: Leo Rasche, et al.
Published: (2023-08-01)

P10: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RESULTS FROM MONUMENTAL-1
by: N. W. C. J van de Donk, et al.
Published: (2022-04-01)

TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPRC5D) CD3 BISPECIFIC ANTIBODY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 STUDY RESULTS
by: JG Berdeja, et al.
Published: (2021-10-01)

S183: NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS FOR TALQUETAMAB (A GPRC5D X CD3 BISPECIFIC ANTIBODY) IN COMBINATION WITH DARATUMUMAB
by: N. W. van de Donk, et al.
Published: (2022-06-01)

689 Pharmacodynamic results with talquetamab and daratumumab in patients with relapsed/refractory multiple myeloma in TRIMM-2
by: Lien Vandenberk, et al.
Published: (2023-11-01)

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS
by: M Mateos, et al.
Published: (2022-04-01)

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
by: Paula Rodriguez-Otero, et al.
Published: (2024-02-01)

Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
by: Paula Rodriguez-Otero, et al.
Published: (2024-03-01)

P888: MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: Ajai Chari, et al.
Published: (2023-08-01)

Talquetamab: A promising immunotherapy for multiple myeloma
by: Amna Tariq, et al.
Published: (2023-10-01)

S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS
by: Nizar J Bahlis, et al.
Published: (2023-08-01)

Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates
by: Christie P. M. Verkleij, et al.
Published: (2021-03-01)

T‐cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions
by: Chloe O'Neill, et al.
Published: (2023-08-01)

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
by: Margaux Lejeune, et al.
Published: (2020-05-01)

Onychomadesis and palmoplantar keratoderma associated with talquetamab therapy for relapsed and refractory multiple myeloma
by: Neha Narayan, BA, et al.
Published: (2023-01-01)

Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma
by: Mashhour Hosny, et al.
Published: (2021-10-01)

P893: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS PHYSICIAN’S CHOICE THERAPY IN TRIPLE-CLASS EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHED COHORT ANALYSIS
by: Albert Oriol, et al.
Published: (2023-08-01)

P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1
by: R. Popat, et al.
Published: (2022-06-01)

P923: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: Hermann Einsele, et al.
Published: (2023-08-01)

P30 SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM)
by: E. Searle, et al.
Published: (2023-05-01)

Bispecific antibodies in indolent B-cell lymphomas
by: Vivek S. Radhakrishnan, et al.
Published: (2024-01-01)

P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1
by: J. Martínez-López, et al.
Published: (2022-06-01)

P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
by: N. van de Donk, et al.
Published: (2023-05-01)

Design and Production of Bispecific Antibodies
by: Qiong Wang, et al.
Published: (2019-08-01)

Bispecific antibodies come to the aid of cancer immunotherapy
by: Ivano Amelio, et al.
Published: (2021-07-01)

ANÁLISE COMPARATIVA ENTRE DARATUMUMABE E TALQUETAMABE NA EFICÁCIA DO TRATAMENTO DE MIELOMA MÚLTIPLO RECIDIVADO E/OU REFRATÁRIO
by: AS Rodrigues, et al.
Published: (2023-10-01)

PB2117: TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY: COMPARATIVE EFFECTIVENESS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: Jing Christine Ye, et al.
Published: (2023-08-01)

Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
by: Freedman, J, et al.
Published: (2017)

Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
by: C. Grandclément, et al.
Published: (2024-03-01)

Design and application of bispecific splice-switching oligonucleotides.
by: Bestas, B, et al.
Published: (2014)

S186: ACQUIRED RESISTANCE TO BISPECIFIC ANTIBODIES BY GENETIC OR EPIGENETIC INACTIVATION OF THE TARGET IN MULTIPLE MYELOMA
by: Jennifer Derrien, et al.
Published: (2023-08-01)

S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL
by: C. Hasselbalch Riley, et al.
Published: (2022-06-01)

Elimination of HIV-1/SHIV infected cells by combinations of bispecific HIV x CD3 DART® molecules
by: M. Tuyishime, et al.
Published: (2019-12-01)

Infectious complications of bispecific antibody therapy in patients with multiple myeloma
by: Beatrice Z. Sim, et al.
Published: (2023-03-01)

P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: R Popat, et al.
Published: (2022-04-01)

A novel carcinoembryonic antigen t cell bispecific antibody (cea tcb) for the treatment of solid tumors
by: Bacac, M, et al.
Published: (2016)

S173: T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: I. Dekhtiarenko, et al.
Published: (2022-06-01)